Pevion Biotech AG said that data from an ongoing first-in-human trial of a therapeutic vaccine against Candida in healthy volunteers elicited high levels of specific antibodies and a 100% mucosal immune response rate. ---Subscribe to MedNous to access this article--- Company News Research & University News
